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Abstract
Background: The unfolded protein response (UPR) plays a pivotal role in ischemia–reperfusion (I/R) injury in various
organs such as heart, brain, and liver. Sodium 4-phenylbutyrate (PBA) reportedly acts as a chemical chaperone that reduces UPR.
In the present study, we evaluated the effect of PBA on reducing the UPR and protecting against myocardial I/R injury in mice.
Methods: Male C57BL/6 mice were subjected to 30-minute myocardial I/R, and were treated with phosphate-buffered saline
(as a vehicle) or PBA. Results: At 4 hours after reperfusion, mice treated with PBA had reduced serum cardiac troponin I levels and
numbers of apoptotic cells in left ventricles (LVs) in myocardial I/R. Infarct size had also reduced in mice treated with PBA at 48 hours
after reperfusion. At 2 hours after reperfusion, UPR markers, including eukaryotic initiation of the factor 2a-subunit, activating
transcription factor-6, inositol-requiring enzyme-1, glucose-regulated protein 78, CCAAT/enhancer-binding protein (C/EBP)
homologous protein, and caspase-12, were significantly increased in mice treated with vehicle compared to sham-operated mice.
Administration of PBA significantly reduced the I/R-induced increases of these markers. Cardiac function and dimensions were
assessed at 21 days after I/R. Sodium 4-phenylbutyrate dedicated to the improvement of cardiac parameters deterioration including
LV end-diastolic diameter and LV fractional shortening. Consistently, PBA reduced messenger RNA expression levels of cardiac
remodeling markers such as collagen type 1a1, brain natriuretic peptide, and a skeletal muscle actin in LV at 21 days after I/R.
Conclusion: Unfolded protein response mediates myocardial I/R injury. Administration of PBA reduces the UPR, apoptosis, infarct
size, and preserved cardiac function. Hence, PBA may be a therapeutic option to attenuate myocardial I/R injury in clinical practice.
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Introduction
Myocardial reperfusion therapy is essential for salvaging
ischemic myocardium in clinical situations. Percutaneous cor-
onary intervention for acute coronary syndrome (ACS) reduces
the mortality rate and the incidence of recurrent ischemia.1
However, reperfusion also has been reported to damage some
of the myocytes that survive the ischemic insult, so-called
lethal ischemia–reperfusion (I/R) injury.2 Potential causes of
this injury include generation of reactive oxygen species, distur-
bances in intracellular calcium, rapid pH restoration, and inflam-
mation.Apotential newcause of I/R injury is the unfoldedprotein
response (UPR). This response occurs in myocardial I/R in vitro
and in vivo and induces myocardial apoptosis.3-5
Under optimal conditions, the endoplasmic reticulum (ER)
is the principal site of folding, synthesis, and modification of
numerous proteins. The accumulation of unfolded or misfolded
proteins and structural mutations of nascent proteins in the ER
is known as ER stress. When it presents, this stress demands the
protein-folding capacity found in the ER and induces the UPR,
which is composed of 3 signaling branches beginning by ER
transmembrane protein sensors. These include protein kinase
R-like ER kinase (PERK), activating transcription factor 6
(ATF6), and inositol-requiring enzyme 1 (IRE1), which serve
as the proximal effectors of the UPR.6 The ER first responds to
ER stresses by releasing molecular chaperones including
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glucose-regulated protein 78 (GRP78), one of the well-studied
molecular chaperones, to maintain protein-folding quality. Upon
removal of the chaperones, PERK oligomerizes and invites the
phosphorylation of eukaryotic initiation of the factor 2a-subunit
(eIF2a), leading to translational arrest and the suppression of
protein synthesis. Activating transcription factor 6 relocates to
the Goldi and is cleaved by proteases, resulting in activating
gene expression that promotes transcription of protein-folding
chaperones and enzymes. Inositol-requiring enzyme 1 oligo-
merizes and splices the messenger RNA (mRNA) that encodes
active X box-binding protein 1, which is the transcription factor
that induces numerous ER stress response genes.7
However, if these adaptive responses fail, the ER triggers
apoptosis to protect the organism by eliminating the damaged
cells. The apoptosis is mediated by the induction of C/EBP
homologous protein (CHOP) or activation of c-Jun NH2-
terminal kinases (JNK) and/or caspase-12-dependent path-
way.8,9 This apoptotic response has been demonstrated in
various diseases including diabetes, cerebral infarction, hepatic
I/R injury, and cardiovascular diseases.10-15 It is of interest that
Miyazaki et al found that the oxidative stress caused by reperfu-
sion activates the UPR pathway in myocardial I/R in CHOP-
deficient mice.10 They also demonstrated that apoptotic cardio-
myocytes in myocardial I/R were most evident at 4 hours after
reperfusion, and myocardial I/R activated UPR markers such as
GRP78, CHOP, and phosphorylated eIF2a (P-eIF2a), which
were elevated as early as 30 minutes to 2 hours after reperfusion.
Sodium 4-phenylbutyrate (PBA) is a low-molecular-
weight fatty acid that is used for the treatment of urea cycle
disorders in clinical settings.16 Sodium 4-phenylbutyrate was
known to act as a chemical chaperone by reducing UPR in
cardiovascular disease, diabetes, cerebral infarction, and
hepatic I/R injury.11-13,17-19 In the current study, we evaluated
whether PBA decreases infarct size and number of apoptotic
cells and improves cardiac function deterioration in mice by
attenuating the UPR after myocardial I/R.
Methods
Animal Care
All animal experiments were approved by the institutional and
governmental animal research committees and were conducted
in accordance with the Guide for the Care and Use of
Laboratory Animals in Kanazawa University, which strictly
conforms to Guide for the Care and Use of Laboratory Animals
published by the US National Institutes of Health (NIH
publication no. 85-23, revised 1996).
Myocardial I/R Protocol
Male C57BL/6 mice (8-12 weeks of age; Charles River Labora-
tories, Yokohama, Japan) were intraperitoneally administered
either phosphate-buffered saline (PBS) as vehicle or PBA
(100mg/kg; Calbiochem, Billerica,Massachusetts) at 30minutes
before surgery.12,13,19,20 The mice were subjected to I/R or sham
operation as described elsewhere.21Briefly, a lateral thoracotomy
was performed in anesthetized and ventilated mice to expose the
heart, and a 7-0 suture was looped under the left coronary artery
(LCA) for induction of a transient myocardial ischemia. After
30 minutes, the LCA was reperfused by releasing the ligature.
A sham operation included all procedures except ligation of the
LCA.
At 2 hours after reperfusion, Western blot analysis of UPR
markers was performed in the samples of LV (sham with vehi-
cle, sham with PBA, I/R with vehicle, and I/R with PBA, n ¼ 5
per group). At 4 hours after reperfusion, the blood samples of
mice were collected and the serums were used for enzyme-
linked immunosorbent assay (ELISA) of serum cardiac
troponin I (cTnI; sham with vehicle, sham with PBA, I/R with
vehicle, and I/R with PBA, n ¼ 5 per group). At the same time,
the left ventricles (LVs) of mice were used for terminal
deoxynucleotidyl transferase dUTP nick end labeling
(TUNEL) staining (I/R with vehicle and I/R with PBA, n ¼ 5
per group). At 48 hours after reperfusion, triphenyltetrazolium
chloride (TTC) staining was performed (I/R with vehicle and
I/R with PBA, n ¼ 8 per group). At 21 days after I/R, echo-
cardiography was performed and lung weight was measured
(sham with vehicle, sham with PBA, I/R with vehicle, and
I/R with PBA, n ¼ 10 per group). Half of their LVs (I/R with
vehicle and I/R with PBA, n¼ 5 per group) were used for Azan
staining, and another half (sham with vehicle, sham with PBA,
I/R with vehicle, and I/R with PBA, n¼ 5 per group) were used
for quantitative real-time polymerase chain reaction (PCR)
assay to evaluate cardiac remodeling markers.
Cardiac Troponin I Measurements
We collected the blood samples 4 hours after reperfusion. The
serum was measured by using a high-sensitive mouse cTnI
ELISA kit (Life Diagnosis, West Chester, Pennsylvania), as
an index of myocardial damage.
Triphenyltetrazolium Chloride Staining
Triphenyltetrazolium chloride staining was performed to eval-
uate the volume of myocardial infarction (MI). At 48 hours
after reperfusion, mice were reanesthetized and LCA was
occluded with same suture. Evans Blue (Sigma-Aldrich,
St. Louis, Missouri) was injected to delineate area at risk
(AAR). Then the hearts were removed and sectioned from
apex to base (4-5 slices). All slices were incubated at 37C
with 1% 2,3,4-triphenyltetrazolium chloride (Wako, Osaka,
Japan) for 15 minutes. The volume of AAR, infarct area
(IA), and LV were multiplied by the weight of the section and
totaled from all sections, performed by a blinded observer.
Analysis of Myocardial Apoptosis
The mice were killed using pentobarbital sodium 4 hours after
reperfusion.Wequalitatively analyzedmyocardial apoptosis using
TUNEL assay (Takara, Shiga, Japan). Briefly, deparaffinized
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sections were incubated with proteinase K, and DNA fragments
were labeled with fluorescein-conjugated dUTP using terminal
deoxynucleotidyl transferase (TdT) (RocheMolecular Biochem-
icals, Mannheim, Germany). Nuclear density was determined by
counting of 40-6-diamidino-2-phenylindole-stained nuclei in 10
fields for each animal using the 20 objective, using BIOREVO
BZ-9000 fluorescence microscopy (Keyence, Japan). The num-
ber of TUNEL-positive nuclei was counted by examination of the
whole LV section, using the same power objective. The counting
was performed by a blinded observer.22
Western Blot Analysis
Western blot analysis was performed to evaluate UPR markers.
At 2 hours after reperfusion, the hearts of mice were removed.
The LV homogenates were prepared in radioimmunoprecipita-
tion assay (RIPA) lysis buffer (Upstate, Lake Placid, New
York) containing 50 mM Tris (pH 7.5), 150 mM NaCl, 1%
IGEPAL CA-630, 0.1% sodium dodecyl sulfate (SDS), deoxy-
cholic acid, 10 mMNa4P2O7, 5 mM EDTA, 0.1 mMNa3VO4, 1
mMNaF, 0.5 mg/mL aprotinin, and 0.5 mg/mL leupeptin. Equal
amount of proteins were loaded, separated by electrophoresis
on SDS-polyacrylamide gels, and transferred onto a polyviny-
lidene fluoride membrane. The following primary antibodies
were used: immunoglobulin heavy-chain binding protein as
GRP78, eIF2a (Cell Signaling Technology, Danvers, Massachu-
setts), P-eIF2a (Abcam, Cambridge, Massachusetts), ATF6,
IRE1, phosphorylated IRE1 (P-IRE1; Novus Biologicals, Little-
ton, Colorado), caspase-12 (Sigma-Aldrich), growth arrest- and
DNAdamage-inducible gene 153 asCHOP, and glyceraldehyde-
3-phosphate dehydrogenase (GAPDH; Santa Cruz Biotechnol-
ogy, Santa Cruz, California). Quantificationwas performed using
the ImageJ software [version 1.45] (NIH).
Echocardiographic Assessment of LV Function
Mice were lightly anesthetized at 21 days after operation, intra-
peritoneally administered with 30 mg/kg of 10% sodium pento-
barbital. Transthoracic echocardiography was performed on the
LV using a 15 to 8 MHz linear transducer interfaced with a
Sonos 5500 (Agilent Technologies [Santa Clara, California],
Philips [Amsterdam, Netherlands]) by an observer who was
blinded to the experimental groups. Left ventricle end-diastolic
diameters (LVEDDs) and LV end-systolic diameters (LVESDs)
were assessed in all groups of mice. Left ventricle fractional
shortening (LVFS) was calculated according to the following
equation: LVFS ¼ ([LVEDD þ LVESD]/LVEDD)  100.
Histological Examination
At 21 days after I/R, mice were reanesthetized and the hearts
were removed. Serial horizontal sections of formalin-fixed,
paraffin-embedded LV of the hearts at the level of the maximal
diameter were subjected to Azan staining for detection of fibro-
sis. The fibrotic areas were quantified in the sections using the
ImageJ software (NIH) performed by a blinded observer.23
Isolation of mRNA and Quantitative Real-Time PCR
At 21 days after I/R, total RNA was isolated using RNeasy
(Qiagen [Germantown, Maryland]) from the LV according to
the manufacturer’s protocol. Total RNA (1 mg) was used to
generate complementary DNA using ReverTra Ace (Toyobo,
Osaka, Japan), according to the manufacturer’s protocol.
Real-time quantitative PCR analysis was performed to eval-
uate cardiac remodeling markers, using the ABI PRISM 7300
sequence detection system (Applied Biosystems, Foster, Cali-
fornia). The following primers and TaqMan probes (Applied
Biosystems) were used: collagen type 1a1 (col1a1;
ID#Mm00801666_g1), brain natriuretic peptide (BNP; Nppb
ID#Mm01255770_g1), and alpha skeletal muscle actin
(aSMA; Acta1 ID#Mm00808212_g1); GAPDH (Gapdh ID#
Mm99999915_g1) was used as an endogenous control.
Statistical Analysis
The data are presented as the mean + standard error of the
mean for each group and were assessed by analysis of variance
with Bonferroni post hoc test for multiple comparisons. The
significance of the differences between the 2 groups was deter-
mined using Student t test. P values < .05 were considered
statistically significant. All statistical analyses were performed
using GraphPad Prism v5.04 software.
Results
Sodium 4-Phenylbutyrate Did Not Affect Hemodynamic
Parameters
Male C57BL/6 mice were intraperitoneally administered PBS
as vehicle or 100 mg/kg of PBA without any operation. Sodium
4-phenylbutyrate administration did not affect heart rate and
systolic/diastolic blood pressure at each time point between the
2 groups (Supplementary Table 1). These results indicate that
there were no significant changes in hemodynamic parameters
with PBA administration.
Sodium 4-Phenylbutyrate Reduced Infarct Size
After Myocardial I/R
To investigate whether PBA administration reduces infarct
size after I/R, we examined serum cTnI at 4 hours after
reperfusion. The level of cTnI was significantly increased
in I/R and lower in PBA-treated mice than in vehicle-treated
mice (Figure 1A and Supplementary Table 2). We also
assessed infarct size using TTC staining at 48 hours after
reperfusion (Figure 1B). The AAR to LV ratio was similar
in the PBA and vehicle groups (54.3% + 4.4% vs 53.8% +
2.0%, no significant difference; Figure 1C). This finding
indicated that the LCA ligation levels were similar between
the 2 groups. The IA to AAR ratio was significantly lower
in the PBA group than in the vehicle group (17.0% + 1.8%
vs 33.7% + 2.3%, P < .01; Figure 1D). The IA to LV ratio
was also lower in the PBA group than in the vehicle group
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(8.9% + 0.8% vs 17.9% + 0.9%, P < .01; Figure 1E).
These results suggest that PBA administration attenuates
MI in myocardial I/R.
Sodium 4-Phenylbutyrate Reduced the Numbers
of Apoptotic Cells After Myocardial I/R
We performed TUNEL staining on the myocardium of mice
treated with PBA and vehicle at 4 hours after reperfusion for
the evaluation of apoptosis (Figure 2A). There were signifi-
cantly fewer TUNEL-positive cells in the PBA group than in
the vehicle group (4.9% + 0.4% vs 8.6% + 1.6%, P < .05;
Figure 2B). These results suggest that apoptosis occurs at
4 hours after myocardial I/R and that PBA administration
reduces I/R-induced apoptosis.
Sodium 4-Phenylbutyrate Attenuated the UPR
After Myocardial I/R
To evaluate whether PBA was acting as a chemical chaperone,
we first assessed the protein levels of GRP78, CHOP, and
P-eIF2a in the whole homogenates of the LV, which were
collected 2 hours after reperfusion. The protein levels of
GRP78, CHOP, and P-eIF2a were elevated in I/R, and these
markers were significantly lower in the PBA group than in the
vehicle group (Figure 3A, B-D). Second, we assessed the pro-
tein levels of caspase-12, ATF6, and P-IRE1. These UPR mar-
kers were also elevated in I/R and were significantly lower in
the PBA group than in the vehicle group (Figure 3A, E-G).
These results suggest that in myocardial I/R, the UPR is
induced at 2 hours after reperfusion, and PBA administration
generally reduces I/R-induced UPR.
Sodium 4-Phenylbutyrate Preserved Cardiac Function
After Myocardial I/R
To investigate whether the reduction in infarct size and the
number of apoptotic cells contributed to the improved car-
diac function, we evaluated lung weight and echocardiogra-
phy at 21 days after I/R. The increases in lung weight to
body weight after I/R, an indicator of lung congestion, were
significantly attenuated in PBA-treated mice compared
with vehicle-treated mice (Figure 4A and Supplementary
Table 3). Echocardiographic measurements showed that
increases in LVEDD and decreases in LVFS after I/R were
observed in I/R, and they were significantly reduced in
PBA-treated mice at 21 days after I/R (Figure 4B, C and
Supplementary Table 4). These findings suggested that the
reduced infarct size in the acute phase of I/R by PBA
administration contributes to improve cardiac function in
the chronic phase of I/R.
Sodium 4-Phenylbutyrate Attenuated Cardiac
Remodeling After Myocardial I/R
At 21 days after I/R, we performed Azan staining of the LV
sections for the detection of fibrosis. The formation of necro-
tic scar and perivascular cardiac fibrosis of remote area was
observed (Figure 5A, B). We quantified the area of fibrosis
in LV sections, and the areas were smaller in PBA-treated
Figure 1. Sodium 4-phenylbutyrate (PBA) reduced infarct size after
myocardial ischemia–reperfusion (I/R). A, Cardiac troponin-I (cTnI) in
the serum of mice treated with vehicle and PBA was measured 4 hours
after reperfusion in myocardial I/R. The level of cTnI was significantly
increased in I/R and lower in PBA-treated mice than in vehicle-treated
mice (**P < .01), n ¼ 5 for all groups. B, 2,3,5-Triphenyltetrazolium
chloride (TTC) staining of myocardial tissue obtained frommice treated
with vehicle and PBA 48 hours after reperfusion to determine the
infarct area. The nonrisk area (NRA) is indicated in blue, area at risk
(AAR) is indicated in red, and the infarct area (IA) is indicated in white.
C-E, Quantification of infarct size by TTC staining in mice treated with
vehicle and PBA at 48 hours after reperfusion. AAR/left ventricle (LV),
ratio of AAR to LV area (C). IA/AAR, ratio of infarct area to AAR (D).
IA/LV, ratio of infarct area to LV area (E). PBA administration reduced
IA/AAR and IA/LV compared with vehicle administration (NS indicates
no significant difference, **P < .01), n¼ 8 for both groups. All results are
presented as mean+ standard error of the mean (SEM).
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mice compared with vehicle-treated mice (5.3% + 1.2% vs
9.9% + 1.5%, P < .05; Figure 5C). The mRNA expression
levels of cardiac remodeling markers, including collagen type
1a1, BNP, and aSMA, were elevated at 21 days after I/R.
Consistent with the results of echocardiographic and histo-
logical measurement, the mRNA expression levels of these
cardiac remodeling markers were significantly decreased in
PBA-treated mice compared with vehicle-treated mice
(Figure 5D-F). These finding suggested that the reduced
infarct size in the acute phase of I/R by PBA administration
contributes to improve cardiac remodeling in the chronic
phase of I/R.
Discussion
In the present study, we demonstrated that PBA protects
against myocardial I/R injury. The major findings in this study
are as follows: (1) PBA reduces apoptotic cell number and
infarct size following myocardial I/R, (2) PBA suppresses the
I/R-induced UPR, and (3) PBA improves cardiac dysfunction
and remodeling after I/R. Thus, PBA reduced myocardial
infarct size and inhibited apoptosis, resulting in improved car-
diac dysfunction after myocardial I/R.
Evidence suggests that myocardial I/R and heart failure are
accompanied by ER stress and the consequent UPR.10,20,24-26
Figure 2. Sodium 4-phenylbutyrate (PBA) reduced apoptotic cells after myocardial ischemia–reperfusion (I/R). A, Representative photographs
of terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) and 40-6-diamidino-2-phenylindole (DAPI)-stained area at risk from
mice treated with vehicle and PBA 4 hours after reperfusion. B, Quantitative analysis of TUNEL-positive cells in whole left ventricle treated with
vehicle and PBA 4 hours after reperfusion. The TUNEL-positive cells are expressed as the percentage of the total myocardium. Sodium
4-phenylbutyrate significantly reduced TUNEL-positive cells compared with vehicle (*P < .05), n ¼ 5 for both groups. All results are presented
as mean + standard error of the mean (SEM).
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Thuerauf et al demonstrated that simulating hypoxia in cultured
rat myocytes increased the expression of GRP78 and other
UPR markers. During hypoxia, protein levels of GRP78
increased in the border zone of the IA early on and declined
after reoxygenation.24 In mouse model, myocardial I/R acti-
vates UPR markers, such as GRP78, CHOP, and P-eIF2a, ele-
vated as early as 30 minutes to 2 hours after reperfusion.10 As
important findings of GRP78, upregulation of GRP78 during
ischemia preconditioning in cardiac myocytes is responsible
for protecting against further ischemic damage.20,27 Activation
of ATF6 in the hearts of transgenic mice was reported to pro-
tect the heart against I/R injury and with upregulation of
GRP78.26 These findings indicate that the UPR induces the
upregulation of GRP78 to restore proper folding, reduce the
accumulation of unfolded proteins caused by myocardial I/R,
and recover ER homeostasis. The functions of chemical cha-
perone are thought to stabilize unfolded proteins, reduce the
aggregation, and partly assist the activity of endogenous cha-
perones including GRP78. This effect of chemical chaperone is
considered to reduce broadly the UPR including the proximal
3 transmembrane proteins sensors.11,28,29 In this study, we
demonstrated that phosphorylation of eIF2a and IRE1, cleaved
form of ATF6, and GRP78 were significantly increased at
2 hours after reperfusion in LV of myocardial I/R, and PBA-
attenuated I/R induces increase of these UPR markers. These
results suggest that PBA attenuates the I/R-induced UPR in
hearts by acting as a chemical chaperone.
The proapoptotic pathway is activated uponcontinued or over-
whelming ER stress. Terai et al demonstrated that the proapopto-
tic pathways ofUPR, includingCHOPexpression and caspase-12
Figure 3. Sodium 4-phenylbutyrate (PBA) attenuated unfolded protein response (UPR) after myocardial ischemia–reperfusion (I/R). Western
blot analyses were performed on whole left ventricular lysates from hearts of mouse 2 hours after reperfusion, treated with vehicle and PBA. A,
Representative Western blots of glucose-regulated protein 78 (GRP78), activating transcription factor-6 (ATF6; cleaved-ATF6), C/EBP-
homologous protein (CHOP), caspase-12 (procaspase-12 and cleaved-caspase-12), inositol-requiring enzyme-1 (IRE1), phosphorylated IRE1
(P-IRE1), eukaryotic initiation of the factor 2a-subunit (eIF2a), phosphorylated eIF2a (P-eIF2a), and glyceraldehyde-3-phosphate dehydrogenase
(GAPDH). B-G, Each expression levels were quantified. GRP78, ATF6, and CHOP were elevated in I/R (GAPDH was used as loading control).
Cleaved-caspase-12 to procaspase-12 ratio was similarly elevated and phosphorylation of IRE1 and eIF2a was invited. Sodium 4-phenylbutyrate
attenuated the increase of these UPR markers compared with vehicle in I/R (*P < .05, **P < .01), n¼ 5 for all groups. All results are presented as
mean + standard error of the mean (SEM).
6 Journal of Cardiovascular Pharmacology and Therapeutics
 by guest on December 4, 2016cpt.sagepub.comDownloaded from 
cleavage, are involved in cardiac myocytes death by hypoxic
stimuli.30 Miyazaki et al found that the oxidative stress caused
by reperfusion activates the induction of CHOP in myocardial
I/R, and apoptotic cell number and infarct size following myo-
cardial I/R were reduced in CHOP-deficient mice.10 Caspase-12
cleaves procaspase-9, leading to caspase-9-dependent activation
of caspase-3. The UPR-induced processing of procaspase-9 can
occur in the absence of cytochrome c release, a finding that sug-
gests that caspase-12 directly triggers caspase-9 activation and
apoptosis independent of themitochondrial cytochrome c/Apaf-1
pathway.31 On the other hand, activation of CHOP by PERK/
eIF2a leads to the upregulation of proapoptotic Bcl-2-interacting
mediator of cell death (Bim) and downregulation of antiapoptotic
factor B-cell lymphoma2 family.32Our study showed thatCHOP
and cleaved caspase-12 were significantly increased after myo-
cardial I/R and that PBA attenuated I/R-induced increases in
them. Consistent with the result, PBA reduced the number of
TUNEL-positive cells after myocardial I/R. The inhibition of
I/R-induced upregulation of the 3 ER transmembrane protein
sensors results in the reduction of UPR-induced apoptosis.
Evidence suggests that PBAs are useful with a reduction of
UPR in various models of cardiovascular diseases such as MI,
cardiac hypertrophy induced by transverse aortic constriction,
cardiac fibrosis induced by isoproterenol, and vascular disease
induced by exposure to saturated fatty acids.17-19,33 However,
other evidences also suggest that the reduction of UPR by PBA
is not useful in all cases. Cardioprotective effect of SO2 pre-
conditioning and local ischemic postconditioning was dimin-
ished by low dose (20 mg/kg) of PBA, which abolished the
upregulation of UPR markers such as GRP78 and ATF6.20,34
But at this time, it is difficult to decide whether these therapies
do not coexist with PBA administration. There remain several
combinations within PBA administration, preconditioning
therapy, and postconditioning therapy. And more, the effica-
cies of them may be influenced by the magnitude of I/R injury
and involved diseases such as diabetes, hypertension, and heart
failure.35,36 This possibility has acquired further study.
The effects of PBA on UPR may be different in each patho-
logical situations influenced by the dose and timing of PBA
administration.17,19,20,34 It should be noted that excessive
reduction of UPR may invite harmful results in some patholo-
gical situations. For example, in CHOP-deficient mice, apop-
totic cell number and infarct size were reduced after
myocardial I/R.10 But in MI model of CHOP-deficient mice,
the acute-phase mortality was increased by cardiac rupture and
the cardiac remodeling was not improved in the chronic
phase.37 These findings may suggest that cell survival or death,
in the UPR, is likely to depend on how much and how long
cardiac myocytes are exposed to various ischemia forms.
On the other hand, PBA is also known as histone deacety-
lase (HDAC) inhibitor, and some HDAC inhibitors have car-
dioprotective effect in myocardial I/R.38,39 Therefore, in our
study, PBA may have partially acted as an HDAC inhibitor
and protected against myocardial I/R injury. Sodium
4-phenylbutyrate may affect I/R injury in known ways and
others that have yet to be proven, but such areas require further
investigation.
We demonstrated that PBA administration not only reduces
infarct size but improves LV remodeling after I/R. Left ven-
tricle infarct size correlated with LV volume and LV ejection
fraction (LVEF) in a rabbit model of MI.40 Larger infarcts
result in greater LV end-diastolic volume and LV end-
systolic volume as well as lower LVEF occurred within 4 weeks
after MI. In the present study, cardiac function was preserved
and cardiac remodeling was prevented at 3 weeks after I/R in
PBA-treated mice. These findings may show that the reduced
infarct size in the acute phase by PBA administration contri-
butes to improve cardiac function and attenuate cardiac remo-
deling in the chronic phase. In this regard, a single
administration of PBA confers some long-term protection.
In conclusion, PBA protects against myocardial I/R injury,
which is evidenced by reduced infarct volume and number of
apoptotic cells, by suppressing excess ER stress. In addition,
these effects contribute to the improvement of cardiac function
Figure 4. Sodium 4-phenylbutyrate (PBA) preserved cardiac function at 21 days after myocardial ischemia–reperfusion (I/R). A. The ratio of lung
weight to body weight was evaluated. Sodium 4-phenylbutyrate attenuated the increases in the ratio of lung weight to body weight compared
with vehicle in I/R (*P < .05), n ¼ 10 for all groups. B and C, Echocardiography was performed. Left ventricular end-diastolic diameter (LVEDD)
and left ventricular fractional shortening (LVFS) were measured. Sodium 4-phenylbutyrate attenuated the enlargement of LVEDD and restored
the reduction of LVFS in I/R (**P < .01), n ¼ 10 for all groups. All results are presented as mean + standard error of mean (SEM).
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and remodeling after I/R in the chronic phase. We propose that
PBAmay be an additional therapeutic option to coronary reper-
fusion therapy for patients with ACS in clinical practice.
Acknowledgment
The authors thank Ayano Nomura for her excellent technical support.
Author Contributions
Osamu Takatori and Soichiro Usui contributed equally to this study.
Declaration of Conflicting Interests
The author(s) declared no potential conflicts of interest with respect to
the research, authorship, and/or publication of this article.
Funding
The author(s) disclosed receipt of the following financial support for
the research, authorship, and/or publication of this article: This work
was partially supported by a Grant-in-Aid for Scientific Research (C)
awarded to S.U.
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compared with mice treated with vehicle (*P < .05), n ¼ 5 for both groups. D-F, Messenger RNA (mRNA) expression levels of cardiac
remodeling markers were quantified by real-time polymerase chain reaction. The expression levels of collagen type 1a1 (D), brain natriuretic
peptide (BNP; E), and alpha skeletal muscle actin (aSMA; F) were normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Sodium
4-phenylbutyrate attenuated mRNA expression of cardiac remodeling markers compared with vehicle in I/R (**P < .01), n¼ 5 for all groups. All
results are presented as mean+ standard error of the mean (SEM).
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